Abstract:Abstract Oral squamous cell carcinoma (OSCC) is a prevalent form of cancer that develops in the oral cavity, globally recognized as the eighth most commonly diagnosed cancer. Despite the application of standard surgical techniques or concurrent chemoradiotherapy, the prognosis for OSCC patients remains unsatisfactory. Initially, cisplatin, the primary and most frequently used chemotherapy agent for treating OSCC, demonstrates effectiveness in therapy. Nonetheless, chemoresistance frequently arises, leading to treatment failure, and this is intricately associated with the activation of hypoxia-inducible factor 1α (HIF-1α) signaling. Recent research has brought to light heightened levels of HIF-1α-mediated vascular endothelial growth factor (VEGF) and BCL-2 in OSCC tumor sites, which play crucial roles in regulating angiogenesis and anti-apoptotic processes within cancer cells. Additionally, interventions aimed at targeting anti-apoptotic molecules or augmenting the expression of pro-apoptotic molecules may represent promising strategies to overcome chemoresistance in OSCC. Therefore, HIF-1α/VEGF/BCL-2 axis could be considered a potential target for the development of chemopreventive and chemotherapeutic strategies for OSCC. Lenvatinib is a targeted multi-kinase inhibitor that can inhibit tumor growth and angiogenesis by blocking the activation of vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptor (PDGFR) α, as well as the proto-oncogenes RET and KIT. However, whether lenvatinib may sensitizes OSCC to cisplatin remains unclear. In our study, we used the MTT assay to prove the cytotoxicity of OSCC cells (SAS and MOC1 cells) was induced by cisplatin and lenvatinib. We employed flow cytometry to verify that the combination of lenvatinib and cisplatin can indeed trigger both extrinsic and intrinsic apoptotic pathways in OSCC cells. Furthermore, our demonstration revealed that the induction of apoptosis pathways by the combination of lenvatinib and cisplatin is associated with mitochondrial-dependent apoptosis and death receptor-dependent apoptosis. Then, transwell invasion and migration assay results proved the inhibition effect of lenvatinib combined with cisplatin in SAS and MOC1 cells. Furthermore, we indicated that the combination of lenvatinib and cisplatin can effectively inhibit angiogenesis and anti-apoptotic mechanisms mediated by the HIF-1α/VEGF/BCL-2 axis in OSCC cells. In summary, our results demonstrate that the combined treatment with lenvatinib and cisplatin enhances the response of OSCC cells under hypoxic conditions. Additionally, it aims to mitigate the negative impact of hypoxia on cisplatin's therapeutic effectiveness and increase the sensitivity of OSCC cells to cisplatin. Citation Format: Ying-Tzu Chen, Yan-Ting Tsai, Fei-Ting Hsu, Hsi-Feng Tu. Evaluate the potential sensitization effect and underlying mechanism of lenvatinib on cisplatin resistance oral squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4736.

Plumbagin Enhances the Anticancer Efficacy of Cisplatin by Increasing Intracellular ROS in Human Tongue Squamous Cell Carcinoma.

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Capsaicin reverses cisplatin resistance in tongue squamous cell carcinoma by inhibiting the Warburg effect and facilitating mitochondrial‐dependent apoptosis via the AMPK/AKT/mTOR axis

Copper-Plumbagin Complex Produces Potent Anticancer Effects by Depolymerizing Microtubules and Inducing Reactive Oxygen Species and DNA Damage

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization.

Bu-Zhong-Yi-Qi Decoction, the Water Extract of Chinese Traditional Herbal Medicine, Enhances Cisplatin Cytotoxicity in A549/DDP Cells through Induction of Apoptosis and Autophagy

Anticancer Effects and Mechanisms of Action of Plumbagin: Review of Research Advances

Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression

Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells

Plumbagin Exhibits Genotoxicity and Induces G2/M Cell Cycle Arrest via ROS-Mediated Oxidative Stress and Activation of ATM-p53 Signaling Pathway in Hepatocellular Cells

Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway

Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity

[Thrichosanthin Enhances Cisplatin-Induced Laryngocarcinoma Apoptosis Through Inhibiting Transcription Factor Nuclear Factor Κb].

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin

Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma

Abstract 4736: Evaluate the potential sensitization effect and underlying mechanism of lenvatinib on cisplatin resistance oral squamous cell carcinoma

Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells

Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop